EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Myasthenia gravis: the future is here

Henry J Kaminski, Patricia Sikorski, S Isabel Coronel, Linda L Kusner

Journal of Clinical Investigation · 17.06.2024 · 134 (12)

DOI: 10.1172/jci179742 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.06.2024. Verfasst von Henry J Kaminski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Rehabilitation Medicine and. Hauptthemen laut MEDLINE: Myasthenia Gravis, Autoantibodies. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) stands as a prototypical antibody-mediated autoimmune disease: it is dependent on T cells and characterized by the presence of autoantibodies targeting proteins located on the postsynaptic surface of skeletal muscle, known as the neuromuscular junction. Patients with MG exhibit a spectrum of weakness, ranging from limited ocular muscle involvement to life-threatening respiratory failure. Recent decades have witnessed substantial progress in understanding the underlying pathophysiology, leading to the delineation of distinct subcategories within MG, including MG linked to AChR or MuSK antibodies as well as age-based distinction, thymoma-associated, and immune checkpoint inhibitor–induced MG. This heightened understanding has paved the way for the development of more precise and targeted therapeutic interventions. Notably, the FDA has recently approved therapeutic inhibitors of complement and the IgG receptor FcRn, a testament to our improved comprehension of autoantibody effector mechanisms in MG. In this Review, we delve into the various subgroups of MG, stratified by age, autoantibody type, and histology of the thymus with neoplasms. Furthermore, we explore both current and potential emerging therapeutic strategies, shedding light on the evolving landscape of MG treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAutoantibodiesHumansReceptors, CholinergicThymomaHistocompatibility Antigens Class IReceptors, FcReceptor Protein-Tyrosine Kinases

Substanzen

AutoantibodiesReceptors, CholinergicMUSK protein, humanHistocompatibility Antigens Class IReceptors, FcReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Neurology and Rehabilitation Medicine and.
  • Department of Pharmacology and Physiology, George Washington University, Washington, DC, USA.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Kaminski, H. J., Sikorski, P., Coronel, S. I., & Kusner, L. L. (2024). Myasthenia gravis: the future is here. Journal of Clinical Investigation, 134(12). https://doi.org/10.1172/jci179742

Vancouver

Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. Journal of Clinical Investigation. 2024;134(12). doi:10.1172/jci179742

BibTeX
@article{Kaminski2024,
  author = {Kaminski, Henry J and Sikorski, Patricia and Coronel, S Isabel and Kusner, Linda L},
  title = {Myasthenia gravis: the future is here},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {12},
  doi = {10.1172/jci179742}
}
Kostenlos starten →